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Abstract
Objectives: To investigate the potential cost savings of using functional platelet assays to confirm the diagnosis of heparin-induced
thrombocytopenia (HIT). Methods: This was a single-center study conducted in the United States. We performed a retrospective
cost of illness analysis of suspected HIT, comparing patients with the serotonin release assay (SRA) ordered as part of their
diagnostic evaluation to those who did not. The primary clinical end point was a composite of mortality and major bleed. Results:
A total of 147 patients met the study’s inclusion criteria. An SRA was ordered in 53 patients of whom 17% were positive. Overall,
SRA use did not reduce the composite primary clinical end point (32.1% vs 33%, P ¼ .911). Also, there was no difference in the
total cost of hospital stay (US $84781.1 vs US $78534.4, P ¼ .409) nor in the direct medical costs related to HIT management
(US $7473.5 vs US $8402.4, P ¼ .393). Early ordering of the SRA (within 48 hours) was associated with shorter length of stay
(20 vs 27 days, P ¼ .029) but without a difference in cost of treatment. Conclusion: The use of SRA did not reduce the costs
or improve clinical outcomes in patients with suspected HIT.
Keywords
cost of illness, direct thrombin inhibitor, heparin, thrombocytopenia, thrombosis

Introduction
Immune-mediated heparin-induced thrombocytopenia (HIT
type II) is a rare complication that affects 0.2% to 5% of all
patients exposed to heparin products and results from the formation of antibodies directed against the heparin/platelet factor
4 (PF4) complex. These antibodies activate platelets and produce a hypercoagulable state that can subsequently lead to an
increased risk of thrombosis (30%-75%), occurring in both the
venous and the arterial vasculature.1,2 Even when managed
with alternative anticoagulants, HIT can be associated with a
dramatic increase in mortality.3
Prompt diagnosis and management of HIT are key to minimize the risk of life-threatening thrombosis. However, diagnosis of this syndrome is challenging and requires correlation
between clinical symptoms and laboratory assays. Measurements of platelet function, such as the serotonin release assay
(SRA), are considered the gold standard diagnostic laboratory
tests due to their ability to detect the underlying hypercoagulable state in patients with true HIT. Although the specificity
and sensitivity of these tests are over 90%, they are very technically demanding to perform and therefore are not widely
available at most institutions.4,5

The more widely available immunologic assays, including
the PF4 enzyme-linked immunosorbent assay (ELISA), are
the most common methods for screening patients for HIT. However, despite their high sensitivity (>95%), immunologic assays
have a relatively low specificity (50%-89%), leading to a high
rate of false positives. The use of optical density (OD), among
other methods, was proposed as a way to increase ELISA specificity.6,7 Similarly, clinical scoring systems, specifically the 4Ts
score, have been used as a tool to identify patients at low risk of
HIT, with a negative predictive value of 91% with the ELISA.8
HIT imposes a significant economic burden on the health
care system. Pharmacoecomnomics studies have shown that
the development of HIT is associated with an increased length
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of stay, as well as an increase in cost of hospitalization.9-14 Previous studies performed in the United States have estimated the
overall cost of management of HIT. However, these studies did
not evaluate the potential cost implications of incorporating a
functional assay in the diagnosis of HIT nor the costs of treating false-positive HIT (ie, false-positive ELISA screening). As
a result of the relatively high false-positive rate associated with
immunologic screening, a significant number of patients may
be exposed to unnecessary diagnostics and drug treatment for
HIT, which could increase their length of stay and augment the
overall economic burden of suspected HIT.
The purpose of this study was to estimate the costs associated with the diagnosis and treatment of suspected HIT and
to explore how the use of functional platelet assays might affect
both the clinical outcomes and the overall costs of this disorder.

Study Methods
This study is a cost-of-illness analysis of suspected HIT from the
health system perspective, conducted at Henry Ford Hospital, an
802-bed, tertiary care, level 1 trauma center in Detroit, Michigan.
This study was approved by the hospital’s institutional review
board. Data were collected retrospectively from patients diagnosed with suspected HIT between January 2007 and October
2011. Suspected HIT was defined as thrombocytopenia necessitating heparin discontinuation, positive ELISA, and initiation of
an alternative anticoagulant. Thrombocytopenia was defined as
a platelet count less than 150 000/mL or a 50% or more reduction
in platelets from baseline following 5 to 10 days of heparin or lowmolecular-weight heparin therapy (or within 24 hours in patients
with recent exposure to heparin products). Based on our institutional guidelines, patients with HIT were started on either argatroban or lepirudin upon diagnosis of suspected HIT. Argatroban
was reserved for those patients with renal dysfunction or those
with previous exposure to lepirudin. The direct thrombin inhibitors (DTIs) and warfarin dosing were managed by a Pharmacist
Directed Anticoagulation Service (PDAS), as directed by a collaborative practice agreement. Warfarin was initiated once platelet
count recovered, then overlapped with the DTI for a minimum of
5 days and until international normalized ratio is within the target
range. At the time of data collection, the PDAS comprised 5 pharmacists who were dedicated to the comprehensive management
of all anticoagulants utilized during the inpatient setting. When
PDAS was not available, DTIs were managed by the other pharmacists, assuring a 24/7 coverage by a pharmacist.15
Patients were excluded if they had a previous heparin allergy
or a history of HIT, if they were not treated with an alternative
anticoagulant, if treatment was stopped before ELISA results
were available, or if treatment duration was not available. Additionally, we excluded cases occurring before 2007, which is when
the specialized pharmacy service (the PDAS) started managing
anticoagulation in all patients with suspected HIT. This time
frame was chosen because the PDAS was shown in a previous
study to improve dosing efficiency and decrease risk of major
bleeding.15 Therefore, this analysis was limited to the time frame
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Table 1. Direct Medical Costs Associated With Suspected HIT.
Laboratory testing
ELISA
SRA
Platelets with or without CBC
PT/INR
aPTT
Diagnostic procedure
Duplex ultrasound (extremities)
CT scan (head, chest, abdomen,
pelvis, and extremities)
MRI (brain)
V/Q scan
Angiography (extremities)
Direct thrombin inhibitor
Argatroban
Lepirudin

Bleeding/blood bank
RBC
Platelets
Cryoprecipitate
FFP
Blood typing, compatibility,
and cross-matching
Surgical intervention
IVC filter placement
Amputation (extremities)
Embolectomy/thrombectomy
(extremities)
Bypass graft (extremities)

Abbreviations: SrCr, serum creatinine; CT, computed tomography; MRI,
magnetic resonance imaging; V/Q, ventilation/perfusion; INR, international
normalized ratio; CBC, complete blood count; IVC, inferior vena cava; RBC,
red blood cell; FFP, fresh frozen plasma; PT, prothrombin time; aPTT, activated
partial thromboplastin time; SRA, serotonin release assay; ELISA, enzymelinked immunosorbent assay; HIT, heparin-induced thrombocytopenia.

that PDAS was available in order to minimize the influence the
service may have on length of stay and bleeding risk.
Patients with the SRA ordered as part of their diagnostic evaluation (SRA) were compared to those who did not (NSRA). ELISA
(LIFECODES1 PF4 Enhanced1 assay; Gen-Probe Incorporated,
Waukesha, Wisconsin) was considered positive irrespective of
OD values since those values were not initially reported and thus
not available for all patients. However, whenever OD was available, these values were reported and classified as weak positive
(OD of 0.4-1) or strong positive (OD > 1). SRA was ordered by the
primary team or as recommended by the pharmacist or the hematology/oncology service. SRA was not performed on site but rather
sent out to multiple outside laboratories. A positive assay was
defined as 20% or greater serotonin release.
The primary clinical end point, a composite of in-hospital
mortality and major bleeding, defined by the International Society on Thrombosis and Haemostasis criteria, was compared
between the SRA and the NSRA groups.16 Secondary clinical
end points included total rate of thrombosis as well as new
thrombosis associated with HIT suspicion. Additionally, cost
analysis according to SRA usage was performed, which included
both the direct medical costs related to HIT management and the
total cost of hospitalization. Direct medical costs included those
associated with the diagnosis of HIT, the use of alternative anticoagulants, and the management of HIT-related complications
(Table 1).
Hospital charges were obtained from the Henry Ford Health
System Corporate Data Store and converted to costs. For each
charge component, we used the specific cost to charge ratio that
corresponds to its revenue center as determined by the hospital
policy. All costs were reported in 2011 US dollar values and a
3%/year inflation rate was applied.
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Patients in the NSRA group were older, more likely to be
African American, and more likely to be female (Table 2).
Additionally, higher thrombosis rates were seen in patients in
the NSRA cohort. No differences were seen in the remaining
clinical baseline characteristics, including the initial diagnosis
at admission. Both groups had similar length of stay prior to
HIT, with a median (range) of 8 days (3-13) of which 4 days
(0-9) were spent in an intensive care unit.

180 patients1

33 excluded
25: History of HIT
5: DTI stopped early 2
3: Unclear duration

Clinical Outcomes
SRA

NSRA

n = 53 (36%)

n = 94 (64%)

Positive SRA

Negative SRA

n = 9 (6%)

n = 44 (30%)

Figure 1. Patient distribution. 1A total of 180 patients met the initial
inclusion criteria: positive enzyme-linked immunosorbent assay
(ELISA) and treatment with a direct thrombin inhibitor (DTI). 2DTI
stopped prior to ELISA results.

A separate subgroup cost analysis was performed to evaluate the cost of false-positive HIT, defined as an initial
positive ELISA, followed by a negative SRA. Additionally,
since the SRA was not available onsite, and was sent to an outside laboratory, we examined the average time delay for results
to be reported. Finally, to account for earlier availability of
those results, patients in whom an SRA was ordered early
(within 48 hours of HIT suspicion) were compared to those
who had a late SRA (after 48 hours of HIT suspicion).

Data Analysis
Data were reported with the use of descriptive statistics and
characterized by mean values with standard deviation or median values with interquartile range, as appropriate. Continuous
data were compared between the 2 groups, with a Student t test
or Mann-Whitney U test, depending on the data distribution.
For categorical data, chi-square or the Fisher exact test was
used, as appropriate. A P value less than .05 was considered
statistically significant.

Results
Patient Characteristics
A total of 180 patients with a positive ELISA and treated with a
DTI were initially screened of which 147 met the inclusion criteria (Figure 1). SRA was performed in 53 patients of which
only 17% were positive. Additionally, ODs were reported in
32 (21.8%) patients. In the SRA group, 0 of the 8 SRAs were
positive in patients with OD of 0.4 to 1 (weak positive) and 3
of the 9 were positive in patients with OD > 1 (strong positive).

The rate of primary composite end point was similar whether
an SRA was ordered or not (32.1% vs 33%, P ¼ .911). No difference in mortality was noted (24.5% vs 26.6%, P ¼ .783).
The median length of stay was 22 days in both the groups
(Table 3). When looking at the number of days spent after HIT
was initially suspected, patients in the SRA group stayed longer
in the hospital, with a median of 16 days, compared to 12 days
in patients in whom no SRA was performed (P ¼ .043).

Cost of Illness
The total cost of hospital stay, per patient, was similar
between the SRA and the NSRA groups (US $84781.1 vs
US $78534.4, respectively, P ¼ .409; Table 4). Additionally,
there was no difference in the total cost after initial suspicion
of HIT, defined by a positive ELISA and DTI started (US
$52202.6 vs US $39285.2, P ¼ .199), nor in the direct medical
costs associated with HIT management (US $7473.5 vs US
$8402.4, P ¼ .733; Table 4).
The use of DTIs accounted for the majority of the direct medical costs, with an average duration of treatment of 8 days in the
SRA group and 7.5 days in the NSRA group (P ¼ .359; Table 3).
The total cost of hospital stay associated with false-positive
ELISA was US $92896.4 per patient (53110.9-147962.1) of
which US $47801.1 (27952.3-89667.7) occurred after the initial suspicion of HIT. Total duration of DTI treatment was
8 days (4.5-11.5) and the direct medical cost associated with
false-positive HIT was US $7624.3 (3865.7-15403.8).

Subgroup Analysis Based on the Timing of the SRA
Since the SRA is sent to an outside laboratory at our institution,
the average time for the results to be reported was approximately
9 days. Subsequently, only 40.9% of the SRA results were
reported during inpatient HIT management. The remaining
samples were reported after the completion of evidence-based
therapy, as directed by the hospital guidelines, and the discontinuation of the DTIs. When available, a negative SRA led to the
discontinuation of the DTIs in most of the patients and subsequently 33.3% of the patients were discharged within 48 hours.
Performing the SRA early (within 48 hours) was associated with
a shorter total length of stay (20 vs 27 days, P ¼ .029), and a
shorter hospitalization after HIT was suspected (12.5 vs 20,
P ¼ .04), although no difference in the cost of treatment was
observed (Table 5). Additionally, the primary clinical outcome
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Table 2. Baseline Characteristics.
Total
N ¼ 147
Age, mean + SD
Female, n (%)
African American, n (%)
Caucasian, n (%)
Serum creatinine, mean + SD
Dialysis, n (%)
Cardiothoracic surgery, n (%)
Active thrombosis prior to HIT, n(%)a
Total days before HIT, median (IQR)
Total ICU days before HIT, median (IQR)
Patient on warfarin prior to HIT, n (%)
Initial anticoagulant, n (%)
Heparin
LMWHb
Initial heparin or LMWH dose, n (%)c
Treatmentd
Prophylaxis
Direct thrombin inhibitor, n (%)
Argatroban
Lepirudin

61.2 + 15.1
72 (49%)
80 (54.4%)
51 (34.7%)
1.8 + 1.7
14 (9.5%)
19 (12.9%)
43 (29.3%)
8 (3-13)
4 (0-9)
20 (13.6%)

NSRA
N ¼ 94
63.8
53
57
26
1.9
11
13
35
8
4
11

(+14.9)
(56.4%)
(60.6%)
(27.7%)
+ 1.7
(11.7%)
(13.8%)
(37.2%)
(4-14)
(0-9.5)
(11.7%)

SRA
N ¼ 53

P value

56.5 (+14.5)
19 (35.8%)
23 (43.4%)
25 (47.2%)
1.6 + 1.7
3 (5.7%)
6 (11.3%)
8 (15.1%)
7 (2-12.5)
4 (0-7.5)
9 (17%)

.005
.017
.044
.017
.296
.231
.663
.005
.119
.599
.370

132 (89.6%)
15 (10.4%)

83 (88.2%)
11 (11.8%)

49 (92.2%)
4 (7.8%)

.454

85 (57.7%)
62 (42.3%)

58 (61.3%)
36 (38.7%)

27 (51%)
26 (49%)

.239

100 (68.3%)
47 (31.7%)

66 (70.7%)
28 (29.3%)

34 (64.1%)
19 (35.9%)

.132

Abbreviations: HIT, heparin-induced thrombocytopenia; LMWH, low-molecular-weight heparin; ICU, intensive care unit; IQR, interquartile range; NSRA, patients
without the SRA; SRA, serotonin release assay; SD, standard deviation; UH, unfractionated heparin.
a
Defined as thrombosis requiring anticoagulation that occurred before HIT was clinically suspected.
b
Most of patients who were on LMWH also received UH at the same hospitalization.
c
Dosing based on hospital protocol.
d
Intravenous UH or subcutaneous LMWH higher than prophylaxis doses.

Table 3. Clinical Outcomes.

Mortality and/or major bleeding, n (%)
Mortality, n (%)
Major bleeding, n (%)
New thrombosis, n (%)a
Any thrombosis, n (%)b
Arterial thrombosis, n (%)
Duration of DTI treatment, median (IQR)
Total hospital stay after HIT, median (IQR)
Total hospital stay, median (IQR)

Total
N ¼ 147

NSRA
N ¼ 94

SRA
N ¼ 53

P value

48 (32.7%)
38 (25.9%)
17 (11.6%)
44 (29.9%)
76 (51.7%)
15 (10.2%)
8 (4-13)
13 (8-21)
22 (15-33.5)

31 (33%)
25 (26.6%)
9 (9.6%)
31 (33%)
55 (58.5%)
10 (10.6%)
7.5 (4-13.2)
12 (7-20)
22 (14-34)

17 (32.1%)
13 (24.5%)
8 (15.1%)
13 (24.5%)
21 (39.6%)
5 (9.4%)
8 (5.5-13.5)
16 (10-22)
22 (16-36.5)

.911
.783
.315
.283
.028
.817
.359
.043
.486

Abbreviations: DTI, direct thrombin inhibitor; HIT, heparin-induced thrombocytopenia; IQR, interquartile range; NSRA, patients without the SRA; SRA, serotonin
release assay.
a
Thrombosis occurring after the initiation of heparin and associated with clinical suspicion of HIT.
b
Any thrombosis occurring before or after anticoagulation.

was numerically lower but statistically insignificant when SRA
was performed earlier (20.8% vs 41.4%, P ¼ .111).

Discussion
Although HIT is a relatively rare condition, treatment of suspected HIT is associated with a large economic burden. Despite
advances in the treatment of this disorder, rates of complications
and mortality are still high, leading to a poor prognosis once
diagnosis is established.17,18 A special importance lies in the
rapid and accurate diagnosis of HIT. And although immunologic

assays are most widely used, their relatively low specificity
increases the risk of false positives and thus augments the overall
cost of illness associated with suspected HIT. Several methods
can be used to increase the accuracy of the diagnosis including
the use of a confirmatory step with the ELISA or using the
4Ts clinical scoring system.6-8 However, platelet activation
assays remain the gold standard for HIT diagnosis.2
In our study, incorporation of the SRA into the diagnostic
workup for suspected HIT did not improve clinical outcomes
nor reduce associated monetary costs, which thus question the
direct utility of this laboratory assay. Additionally, the low rate
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Table 4. Median Costs (IQR) Based on Whether an SRA Was Part of Diagnostic Workup (USD).

Before HIT was suspected
After HIT was suspecteda
Laboratory
Imaging
Pharmacy
Blood bank
Operation room
Hospital stay-other
Direct HIT management
Laboratory
Imaging
Direct thrombin inhibitors
Blood bank
Surgical intervention
Total cost

SRA

NSRA

P value

28897.8 (6146.4-50949.9)
52202.6 (27750.7-87557.6)
1493.3 (515.4-2746.4)
1758.6 (754.8-3194.4)
10927.2 (5281.2-18427.7)
414.3 (22.3-2094.2)
606.9 (84.7-4256.7)
33936.1 (16342.2-58971.6)
7473.5 (3865.7-14578.7)
137.0 (115-288.4)
80.3 (0-149.9)
5753.0 (2775.6-14241.5)
414.3 (22.3-2094.2)
0 (0-0)
84781.1 (54767.9-140081.0)

27159.9 (10097.1-64079.2)
39285.2 (22750.2-80179.5)
843.5 (370.2-2124.2)
1404.0 (471.6-3067.2)
10502.9 (5154.8-17787.3)
186.9 (0-855.1)
282.6 (0-1762.9)
24623.8 (12170.1-46765.5)
8402.4 (3551.0-15376.1)
153.4 (89.1-255.3)
75.3 (0-194.2)
7458.7 (3022.4-14945.2)
186.9 (0-855.1)
0 (0-0)
78534.4 (43169-143640.9)

.616
.199
.014
.228
.645
.024
.062
.088
.733
.516
.981
.697
.024
.227
.409

Abbreviations: DTI, direct thrombin inhibitor; ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; IQR, interquartile range;
NSRA, patients without the SRA; SRA, serotonin release assay.
a
Defined by a positive ELISA screening and treatment with a DTI.

Table 5. Median Costs (IQR) Based on When the SRA Was Performed.

Before HIT was suspected
After HIT was suspecteda
Laboratory
Imaging
Pharmacy
Blood bank
Operation room
Hospital stay-other
Direct HIT management
Laboratory
Imaging
Direct thrombin inhibitors
Blood bank
Surgical intervention
Total cost

Late SRA (>48 h)

Early SRA (48 h)

P value

34385.2 (6331.3-49477.4)
60196.5 (28215.8-124070.5)
2083.9 (656.8-4767.9)
2567.6 (757.2-4035.8)
11218.6 (5444.8-19933.5)
721.9 (40.9-2616.5)
507.4 (100.1-4985.5)
41099.5 (20091.8-72551.4)
8076.8 (4952.9-15769.4)
198.7 (119.1-348.1)
87.5 (14.9-187.9)
5784.1 (2775.6-14684.5)
721.9 (40.9-2616.5)
0 (0-0)
92208.5 (70308.1-221936.8)

21212.3 (6146.4-67625.1)
45341.3 (19136.9-73232.0)
1367.9 (428.8-2071.9)
1249.4 (726.5-2805.6)
10157.5 (4853.6-17131.4)
353.9 (0-1104.0)
1216.5 (0-3452.9)
29289.9 (12948.3-45847.7)
7264.4 (2610.1-14578.7)
126.0 (113.3-170.7)
66.1 (0-136.1)
5753.0 (2691.3-13928.8)
353.9 (0-1104)
0 (0-0)
73414.9 (31119.9-129853.1)

.820
.272
.096
.179
.681
.181
.747
.219
.354
.078
.276
.842
.181
.839
.185

Abbreviations: DTI, direct thrombin inhibitor; ELISA, enzyme-linked immunosorbent assay; HIT, heparin-induced thrombocytopenia; IQR, interquartile range;
NSRA, patients without the SRA; SRA, serotonin release assay.
a
Defined by a positive ELISA screening and treatment with a DTI.

of positive SRA results suggests that HIT is likely being overly
suspected. This outlines the need to carefully interpret ELISA
results in the context of the clinical presentation as an initial
diagnostic approach while awaiting the confirmatory SRA
results. The SRA would thus be of a potential benefit for those
with extended duration of DTI treatment and as a valuable tool
for subsequent use of heparin products.
Alternatively, the absence of cost reduction in our study
might have been due, in part, to the significant delay in the
reporting of the SRA results, which might have prevented clinicians from incorporating those results early into the clinical
decision process. This is supported by the fact that ordering the
SRA earlier during the diagnostic workup was associated with
a reduction in hospital stay although no difference in costs was

observed. Additionally, once available, negative results lead to
the discontinuation of DTIs and hospital discharge in a significant proportion of patients. This suggests that clinicians are
reacting to SRA results and that earlier ordering and reporting
might have the potential to significantly reduce the cost and
duration of hospitalization, specifically for patients with
false-positive ELISA screening. The slow turnaround time of
the SRA is in part due to the fact that it is not done in most hospitals but rather sent out to an outside laboratory as it is performed by skilled technicians in a radioisotope facility. As
such, a cost–benefit analysis of performing this test within each
hospital is needed.
Previous studies done in the United States have examined the
cost of illness associated with this disorder. Those studies utilized
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different definitions of HIT and had different study designs, leading to a different estimation of the cost of care.9-14 The key difference between the previous literature and our study is that we
examined the costs of all suspected HIT and separated the costs
of true- and false-positive results as confirmed subsequently by
an SRA. As such, this is the first study to examine the financial
benefit of using functional tests in the diagnostic workup of
patients with suspected HIT and the potential decrease in the cost
of care associated with false-positive ELISA screening.
An interesting finding was the low rate of positive SRA tests
for which several explanations can be proposed. First, as previously stated, this may reflect a low threshold to screen for HIT,
especially in situations where high incidence of false-positive
ELISA is known to occur, such as patients who have undergone
a cardiothoracic surgery. On the other hand, this low rate may
suggest a possible selection bias in which patients with a relatively low suspicion for HIT were ordered a confirmatory SRA
whereas in those with higher level of suspicion (ie, thrombosis),
a positive ELISA was considered sufficient to diagnose HIT. And
this is likely why the NSRA group had a higher rate of thrombosis.
The results of this study must be viewed in the context of several limitations. First, the direct medical costs associated with HIT
are underestimated as we did not account for the possible increase
in length of stay, in which patients stayed in the hospital simply to
be actively treated with an alternative anticoagulant. However, as
no difference was seen in the length of stay, and as no evidence
exists to suggest that the use of SRA may affect hospital stay,
including this particular cost component would not have affected
the results. Also, since this was a retrospective observational
study, confounding factors cannot be completely ruled out. This
was manifested in a longer hospital stay after HIT was suspected
in the SRA group as well as some differences in the baseline characteristics. Finally, the generalizability of our results to other
institutions will depend on the availability of SRA onsite and its
turnaround time, the preferred alternative anticoagulant, the strategy used for waste minimization of these agents as well as the
responsible provider for DTI management. At our institution, this
latter is performed by a specialized pharmacy service, a strategy
shown to improve dosing efficiency and decrease risk of major
bleeding.15
In conclusion, the diagnosis and treatment of suspected HIT,
including those associated with a false-positive ELISA screening, are associated with significant health care costs. The use of
SRA was not associated with a benefit on clinical or financial
outcomes. Further studies are needed to determine the benefit
of having earlier access to the results by performing this assay
within each health system.
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